ALRT 1057 topical 9-cis-retinoic acid and Targretin topical LGD1069 selective activator of the RXR retinoid receptor data

Interim Phase I/IIb results of the ALRIZ (San Diego) retinoid and the LGND compound were presented at the Cowen & Co. conference in San Francisco, with positive findings in about half of the patients evaluable so far.

ALRT 1057 cream gave partial or complete responses in one or more treated lesions in the majority (65 percent) of 20 patients evaluated so far, who have received at least two months of treatment. ...